首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IFNa3 |
| Uniprot No | O14879 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-490aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSMSEVTKNSLEKILPQLKCHFTWNLFKE DSVSRDLEDRVCNQIEFLNTEFKATMYNLLAYIKHLDGNNEAALECLRQA EELIQQEHADQAEIRSLVTWGNYAWVYYHLGRLSDAQIYVDKVKQTCKKF SNPYSIEYSELDCEEGWTQLKCGRNERAKVCFEKALEEKPNNPEFSSGLA IAMYHLDNHPEKQFSTDVLKQAIELSPDNQYVKVLLGLKLQKMNKEAEGE QFVEEALEKSPCQTDVLRSAAKFYRRKGDLDKAIELFQRVLESTPNNGYL YHQIGCCYKAKVRQMQNTGESEASGNKEMIEALKQYAMDYSNKALEKGLN PLNAYSDLAEFLETECYQTPFNKEVPDAEKQQSHQRYCNLQKYNGKSEDT AVQHGLEGLSISKKSTDKEEIKDQPQNVSENLLPQNAPNYWYLQGLIHKQ NGDLLQAAKCYEKELGRLLRDAPSGIGSIFLSASELEDGSEEMGQGAVSS SPRELLSNSEQLN |
| 预测分子量 | 58 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IFNa3重组蛋白的3篇参考文献及其摘要概述：
1. **《High-level expression and purification of recombinant human interferon alpha 3 in E. coli》**
- 作者：Zhang Y, et al.
- 摘要：该研究报道了利用大肠杆菌表达系统高效生产重组人IFN-α3的方法，通过优化诱导条件和亲和层析技术获得高纯度蛋白，并证实其具有抗病毒活性。
2. **《Functional characterization of recombinant interferon alpha 3 in antiviral therapy》**
- 作者：Li H, et al.
- 摘要：文章评估了IFN-α3重组蛋白在体外和动物模型中的抗病毒效果，显示其对丙型肝炎病毒(HCV)复制的显著抑制作用，并探讨了其与IFN-α2b的活性差异。
3. **《Structural and immunomodulatory analysis of engineered IFN-α3 variants》**
- 作者：Wang J, et al.
- 摘要：研究通过基因工程技术改造IFN-α3结构，分析不同突变体对免疫细胞因子的调控能力，发现特定突变体可增强抗肿瘤免疫应答，为优化干扰素疗法提供依据。
注：以上文献信息为模拟示例，实际研究中建议通过PubMed或专业数据库检索最新文献。
Interferon alpha-3 (IFNα3), a member of the type I interferon family, is a naturally occurring cytokine produced by immune cells, particularly plasmacytoid dendritic cells, in response to viral infections or other pathogenic stimuli. It plays a critical role in innate immunity by binding to the interferon-α/β receptor (IFNAR) and activating the JAK-STAT signaling pathway, which induces the expression of interferon-stimulated genes (ISGs). These genes mediate antiviral, antiproliferative, and immunomodulatory effects, including viral replication inhibition, immune cell activation, and tumor suppression.
Recombinant IFNα3 is a genetically engineered version of the native protein, typically produced using bacterial (e.g., *E. coli*) or mammalian expression systems. This recombinant approach ensures high purity, consistency, and scalability for therapeutic or research applications. Structurally, it retains the conserved features of type I IFNs, such as a compact helical bundle, but differs from other IFNα subtypes in specific amino acid residues, which may influence receptor binding affinity and biological activity.
Clinically, recombinant IFNα3 has been explored for treating viral infections (e.g., hepatitis B/C), cancers (e.g., melanoma, leukemia), and autoimmune disorders. Its therapeutic potential stems from its ability to enhance antigen presentation, activate natural killer cells, and inhibit angiogenesis. However, like other interferons, systemic administration can cause side effects such as flu-like symptoms, myelosuppression, or autoimmune reactions.
Research continues to optimize IFNα3 variants for improved efficacy and reduced toxicity, including pegylated forms for prolonged half-life or engineered fusion proteins. Additionally, it serves as a tool in immunology studies to dissect subtype-specific signaling and functional differences within the IFNα family. Despite the emergence of targeted therapies, IFNα3 remains a benchmark in understanding interferon biology and antiviral defense mechanisms.
×
